Tumor neuroendocrine pankréas (NETs) biasana tumuwuh lalaunan, sareng laboratorium ngawas tumor pikeun tanda-tanda kamekaran ngaliwatan tés pencitraan. Pasén anu nyebarkeun NET tina pankréas biasana ngagaduhan gejala sapertos diare atanapi masalah hormonal. Éta tiasa dianggo pikeun ubar sapertos octreotide, lanreotide, diazoxide, sareng inhibitor pompa proton, anu tiasa ngahambat kamekaran tumor.
When the patient’s symptoms cannot be controlled or the scan shows signs of tumor growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
Upami sadaya pangobatan anu tiasa dianggo henteu tiasa dianggo deui, maka pertimbangkeun ilubiung dina uji klinis pikeun nguji terapi anyar. Partisipasi dina uji klinis kamungkinan nguntungkeun sababaraha pasien.
